Advances in recurrence risk assessment of gastrointestinal stromal tumor.
10.3760/cma.j.cn441530-20211216-00500
- Author:
D J SONG
1
;
L T YANG
2
Author Information
1. Department of Interventional Therapy, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou 310022, China.
2. Department of Gastric Surgery, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou 310022, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Gastrointestinal Stromal Tumors/surgery*;
Risk Assessment;
Prognosis;
Risk Factors;
Neoplasm Recurrence, Local;
Retrospective Studies
- From:
Chinese Journal of Gastrointestinal Surgery
2022;25(12):1138-1143
- CountryChina
- Language:Chinese
-
Abstract:
Identification of prognosis-related risk factors and accurate assessment of risk stratification in patients with gastrointestinal stromal tumor (GIST) is of great significance not only for establishing a reliable prognostic model and developing a follow-up plan but also for selecting potential populations benefiting from neoadjuvant therapies. Although several risk stratification models have been established, it is still challenging to accurately assess patients' risk of recurrence, and the performance of these prediction models still needs to be improved. This review focused on the latest studies in recurrence risk assessment for GIST patients, and summarized potential predictive markers and recurrence risk models related to tumor-related characteristic parameters, novel laboratory examinations, radiological imaging signatures and molecular pathological features, which could provide a reference for accurate risk stratification and individualized targeted therapies for GIST patients.
